Fibronostics Secures Financing, Announces New CEO

Fibronostics, a global leader in noninvasive, AI-driven diagnostics for NASH patients, announced it has secured $6.5 million in funding. In addition to the financing, Sven Henrichwark, Ph.D., has been named the company's CEO.